Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-center, Open-label, Single-arm, Before and After Switch Study to Evaluate the Efficacy, Safety and Tolerability of Alemtuzumab in Paediatric Patients With Relapsing Remitting Multiple Sclerosis (RRMS) With Disease Activity on Prior Disease Modifying Therapy (DMT)

Trial Profile

A Multi-center, Open-label, Single-arm, Before and After Switch Study to Evaluate the Efficacy, Safety and Tolerability of Alemtuzumab in Paediatric Patients With Relapsing Remitting Multiple Sclerosis (RRMS) With Disease Activity on Prior Disease Modifying Therapy (DMT)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alemtuzumab (Primary) ; Aciclovir; Cetirizine; Dexchlorpheniramine; Diphenhydramine; Glatiramer acetate; Histamine H1 receptor antagonists; Histamine H1 receptor antagonists; Histamine H2 receptor antagonists; Interferon beta; Interferon beta; Methylprednisolone; Paracetamol; Prednisolone; Ranitidine
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms LemKids; na
  • Sponsors Sanofi Genzyme
  • Most Recent Events

    • 10 Jan 2024 This trial has been completed in Poland, according to European Clinical Trials Database record.
    • 19 Dec 2022 This trial has been Discontinued in Italy, according to European Clinical Trials Database record
    • 07 Apr 2021 Planned primary completion date changed from 1 Dec 2025 to 1 May 2021.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top